<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34889531</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2574-173X</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology reports</Title><ISOAbbreviation>Neuropsychopharmacol Rep</ISOAbbreviation></Journal><ArticleTitle>Severe and long-lasting neuropsychiatric symptoms after mild respiratory symptoms caused by COVID-19: A case report.</ArticleTitle><Pagination><StartPage>114</StartPage><EndPage>119</EndPage><MedlinePgn>114-119</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/npr2.12222</ELocationID><Abstract><AbstractText Label="BACKGROUND">Coronavirus disease 2019 (COVID-19) is known to cause not only respiratory but also neuropsychiatric symptoms, which are assumed to be derived from a cytokine storm and its effects on the central nervous systems. Patients with COVID-19 who develop severe respiratory symptoms are known to show severe neuropsychiatric symptoms such as cerebrovascular disease and encephalopathy. However, the detailed clinical courses of patients with neuropsychiatric symptoms caused by mild or asymptomatic COVID-19 remain poorly understood. Here, we present a case of COVID-19 who presented with severe and prolonged neuropsychiatric symptoms subsequent to mild respiratory symptoms.</AbstractText><AbstractText Label="CASE PRESENTATION">A 55-year-old female with COVID-19 accompanied by mild respiratory symptoms showed delusion, psychomotor excitement, and poor communication ability during quarantine outside the hospital. Considering her diminished respiratory symptoms, her neuropsychiatric symptoms were initially regarded as psychogenic reactions. However, as she showed progressive disturbance of consciousness accompanied by an abnormal electroencephalogram, she was diagnosed with post-COVID-19 encephalopathy. Although her impaired consciousness and elevated cytokine level improved after steroid pulse therapy, several neuropsychiatric symptoms, including a loss of concentration, unsteadiness while walking, and fatigue, remained.</AbstractText><AbstractText Label="CONCLUSIONS">This case suggests the importance of both recognizing that even apparently mild COVID-19-related respiratory symptoms can lead to severe and persistent neuropsychiatric symptoms, and elucidating the mechanisms, treatment, and long-term course of COVID-19-related neuropsychiatric symptoms in the future.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley &amp; Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jozuka</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-0610-7904</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uematsu</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujigaki</LastName><ForeName>Hidetsugu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Science, Toyoake, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Yasuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Science, Toyoake, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawabata</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Haruki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inada</LastName><ForeName>Toshiya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8427-5639</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Kuniaki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Science, Toyoake, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozaki</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP21dk0307099</GrantID><Agency>AMED</Agency><Country/></Grant><Grant><GrantID>JP21dk0307103</GrantID><Agency>AMED</Agency><Country/></Grant><Grant><GrantID>21H02848</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuropsychopharmacol Rep</MedlineTA><NlmUniqueID>101719700</NlmUniqueID><ISSNLinking>2574-173X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">encephalopathy</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>8</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34889531</ArticleId><ArticleId IdType="pmc">PMC8919122</ArticleId><ArticleId IdType="doi">10.1002/npr2.12222</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID&#x2010;19. Lancet Neurol. 2020;19(9):767&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar&#x2010;Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta&#x2010;analysis with comparison to the COVID&#x2010;19 pandemic. Lancet Psychiatry. 2020;7(7):611&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID&#x2010;19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Anrather J, Kamel H. Effects of COVID&#x2010;19 on the Nervous System. Cell. 2020;183(1):16&#x2013;27 e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437501</ArticleId><ArticleId IdType="pubmed">32882182</ArticleId></ArticleIdList></Reference><Reference><Citation>Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, et al. Frequent neurologic manifestations and encephalopathy&#x2010;associated morbidity in Covid&#x2010;19 patients. Ann Clin Transl Neurol. 2020;7(11):2221&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7664279</ArticleId><ArticleId IdType="pubmed">33016619</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugin D, Vargas MI, Thieffry C, Schibler M, Grosgurin O, Pugin J, et al. COVID&#x2010;19&#x2010;related encephalopathy responsive to high&#x2010;dose glucocorticoids. Neurology. 2020;95(12):543&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32680950</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S, et al. Steroid&#x2010;responsive encephalitis in coronavirus disease 2019. Ann Neurol. 2020;88(2):423&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276848</ArticleId><ArticleId IdType="pubmed">32418288</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfil M, Selby L, Van Schooneveld TC, Fadul N. Acute psychosis associated with recent SARS&#x2010;CoV&#x2010;2 infection: a case report. Idcases. 2021;24:e01140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8076759</ArticleId><ArticleId IdType="pubmed">33936950</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim&#x2010;Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID&#x2010;19 severity and survival. Nat Med. 2020;26(10):1636&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Canham LJW, Staniaszek LE, Mortimer AM, Nouri LF, Kane NM. Electroencephalographic (EEG) features of encephalopathy in the setting of Covid&#x2010;19: a case series. Clin Neurophysiol Pract. 2020;5:199&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7329683</ArticleId><ArticleId IdType="pubmed">32838076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, et al. Microvascular Injury in the Brains of Patients with Covid&#x2010;19. N Engl J Med. 2021;384(5):481&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Espindola OM, Gomes YCP, Brandao CO, Torres RC, Siqueira M, Soares CN, et al. Inflammatory cytokine patterns associated with neurological diseases in coronavirus disease 2019. Ann Neurol. 2021;89(5):1041&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014707</ArticleId><ArticleId IdType="pubmed">33547819</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, et al. Blood&#x2010;brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimers Dement. 2018;14(12):1640&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">30120040</ArticleId></ArticleIdList></Reference><Reference><Citation>Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med. 2002;8(10):483&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12383771</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas&#x2010;Massana A, et al. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID&#x2010;19. BMC Neurol. 2020;20(1):248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301053</ArticleId><ArticleId IdType="pubmed">32552792</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry &#x2010; novel perspectives on brain disorders. Nat Rev Neurol. 2019;15(6):317&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">30988501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura H, Mori D, Aleksic B, Ozaki N. Elucidation of molecular pathogenesis and drug development for psychiatric disorders from rare disease&#x2010;susceptibility variants. Neurosci Res. 2021;170:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33316300</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F. Gemelli against C&#x2010;P&#x2010;ACSG. persistent symptoms in patients after acute COVID&#x2010;19. JAMA. 2020;324(6):603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Espindola OM, Brandao CO, Gomes YCP, Siqueira M, Soares CN, Lima M, et al. Cerebrospinal fluid findings in neurological diseases associated with COVID&#x2010;19 and insights into mechanisms of disease development. Int J Infect Dis. 2021;102:155&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7591319</ArticleId><ArticleId IdType="pubmed">33127503</ArticleId></ArticleIdList></Reference><Reference><Citation>Miglis MG, Prieto T, Shaik R, Muppidi S, Sinn DI, Jaradeh S. A case report of postural tachycardia syndrome after COVID&#x2010;19. Clin Auton Res. 2020;30(5):449&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7471493</ArticleId><ArticleId IdType="pubmed">32880754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama T, Hongo Y, Kaida K, Kano O. Guillain&#x2010;Barre syndrome after COVID&#x2010;19 in Japan. BMJ Case Rep. 2020;13(10):e239218. doi:10.1136/bcr-2020-239218</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-239218</ArticleId><ArticleId IdType="pmc">PMC7597510</ArticleId><ArticleId IdType="pubmed">33122241</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. Long COVID in a prospective cohort of home&#x2010;isolated patients. Nat Med. 2021;27(9):1607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalan IP, Marti CR, Sota DP, Alvarez AC, Gimeno MJE, Juana SF, et al. Corticosteroids for COVID&#x2010;19 symptoms and quality of life at 1 year from admission. J Med Virol. 2021, 94(1):205&#x2013;10. doi:10.1002/jmv.27296</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27296</ArticleId><ArticleId IdType="pmc">PMC8662039</ArticleId><ArticleId IdType="pubmed">34436783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>